arTreg for Liver Transplant (LITTMUS-UCSF Trial)

"Affirmative. Clinicaltrials.gov's information implies that this experiment is actively seeking participants, with the original post dated April 22nd 2021 and last edited on September 13th 2022. The investigators are in pursuit of 9 individuals from 1 clinical centre to participate in the trial."

"Patients suffering from multiple sclerosis, leukemia, myelocytic acute and transplant rejection can benefit from arTreg therapy. Additionally, this treatment is applicable to those with kidney conditions."

"According to clinicaltrials.gov, enrolment for this medical trial is open and ongoing. It was initially published on April 22nd 2021 and revised most recently on September 13th 2022."

"PPD, the study sponsor of this clinical trial, has reported that its primary measure for success is the Number and Severity of Adverse Events (AEs) Attributed to arTreg. Secondary metrics include incidents of Chronic Rejection Events at any time after Alloantigen-Reactive Tregs infusion, Number of Participants who Develop a Malignancy and Incidence of ≥Grade 3 Infections Following arTreg Infusion. These outcomes will be evaluated over an observation period spanning 52 weeks (+/- 4)."

"The inclusionary standards of this trial necessitate that participants must fall within the 18-70 age bracket. For individuals younger than 18, there are 306 studies available; for those over 65, 749 studies exist."

"Presently, there are 909 research projects centred around arTreg. This includes 170 trials in their third stage of development. While Philadelphia is the hub for studies surrounding this treatment, it has also been trialled at 31859 other locations globally."

"This medical trial is searching for nine individuals with a history of liver transplantation in the age range 18-70. Essential criteria include an understanding and agreement to give informed consent, being listed as either a living or deceased donor candidate for primary solitary liver transplatnation, contraception use when applicable, sustained viral response from hepatitis c treatment over 24 weeks prior to transplant if HCV positive, immunizations up-to-date based on ACIP recommendations unless deemed unnecessary by investigator; meeting eligibility requirements specific to the clinical site they are donating at; commitment to provide biologic samples; and fulfilling further site-specific clinical donor requisites."